10-Q: Arcadia Biosciences Reports Q3 2026 Results Amidst Financial Challenges

Arcadia Biosciences, Inc. reported a revenue increase for Q3 2026 but faces substantial doubt about its ability to continue as a going concern, alongside ongoing Nasdaq listing compliance issues.

Summary

• Arcadia Biosciences, Inc. reported total revenues of $1.619 million for the three months ended September 30, 2026, a 24% increase compared to $1.302 million in the same period of 2025, driven by strong volumes.
• The company reported a net income attributable to common stockholders of $1.755 million for the three months ended September 30, 2026, a significant improvement from a net loss of $1.003 million for the nine months ended September 30, 2025.
• However, for the nine months ended September 30, 2026, the company reported a net loss of $8.896 million.
• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient cash to meet anticipated requirements for the next 12 months.
• The company is facing challenges in meeting Nasdaq's continued listing requirements, including minimum bid price and minimum stockholders' equity.
• The company sold the GoodWheat brand to Above Food for $3.7 million in May 2024, but Above Food defaulted on its promissory note payments.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant going concern issues, continued net losses, and ongoing Nasdaq listing compliance challenges, despite a revenue increase.

Positives

• Product revenues increased by 24% to $1.619 million for the three months ended September 30, 2026, compared to the same period in 2025, driven by strong volumes.
• Cost of revenues decreased by 14% to $760,000 for the three months ended September 30, 2026, compared to the same period in 2025, partly due to an IEEPA tariffs refund.
• Selling, general, and administrative expenses decreased by 26% to $4.004 million for the nine months ended September 30, 2026, compared to the same period in 2025, due to the absence of M&A expenses and lower employee costs.
• The company reported a net income of $1.755 million for the three months ended September 30, 2026, a significant improvement from the prior year's comparable period.

Negatives

• The company reported a net loss of $8.896 million for the nine months ended September 30, 2026.
• Substantial doubt exists about the company's ability to continue as a going concern, with cash and cash equivalents of $2.8 million as of September 30, 2026, insufficient for the next 12 months.
• Above Food defaulted on its $2.0 million principal payment plus accrued interest due in May 2025 on the promissory note, and substantial doubt exists about future payments.
• The company received a notice from Nasdaq for failing to meet the minimum bid price requirement (closing bid price below $1.00 for 30 consecutive business days).
• The company also received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement ($633,000 as of June 30, 2026, below the $2.5 million requirement).
• The company's common stock is at risk of delisting from Nasdaq due to non-compliance with listing rules.

Risks

• Failure to meet Nasdaq's continued listing requirements could result in delisting, negatively impacting market price, liquidity, and access to capital markets.
• The company's ability to continue as a going concern is uncertain due to insufficient cash resources to meet anticipated cash requirements for at least the next 12 months.
• Above Food's default on its promissory note and the uncertainty surrounding the issuance of additional Parent Shares create significant financial risk.
• The company is subject to a lawsuit alleging violations of California's Proposition 65 regarding Bisphenol A (BPA) in coconut water containers.
• Tariff uncertainty remains regarding future rates and applicable countries/products, despite some refunds received.
• The company's common stock may be delisted from Nasdaq if it fails to regain compliance with minimum bid price and stockholders' equity requirements.

Future Outlook

The company believes its existing cash and cash equivalents will not be sufficient to meet anticipated cash requirements for at least the next 12 months, raising substantial doubt about its ability to continue as a going concern. Additional funding through debt or equity financings, or sales of assets, may be sought. There is substantial uncertainty regarding future tariff rates. The company expects to launch a newly formulated Espresso in a new 1-liter size in November 2026, followed by a new 10.5-ounce slim-can line in the first half of 2027.

Management Comments

• The strategic decision to sell GoodWheat enabled the Company to monetize its intellectual property early.
• The Company intends to vigorously defend itself against the claims in the Proposition 65 lawsuit.
• The Company is carefully monitoring its MVLS and is actively considering alternatives, actions and transactions to address its MVLS, including without limitation the possibility of a merger, acquisition or other strategic transaction or a financing transaction.
• We intend to monitor the closing bid price for our common stock and will consider available strategies in an effort to satisfy the minimum bid price requirement.

Industry Context

StockSavvy.ai notes that Arcadia Biosciences operates in the consumer goods sector, specifically with its Zola coconut water brand. The company's financial performance is impacted by consumer demand, supply chain costs (including tariffs), and its ability to manage its financial obligations. The ongoing challenges with Nasdaq listing requirements and going concern issues are significant headwinds that are not uncommon for companies in competitive and capital-intensive industries, especially those undergoing strategic shifts or facing market volatility.

Legal Proceedings

• The company is a defendant in a lawsuit alleging violations of California's Proposition 65 regarding Bisphenol A (BPA) in coconut water containers, seeking injunctive relief and civil penalties.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern issues, potential delisting from Nasdaq, and the possibility of substantial dilution from future equity financings.
• Creditors may face uncertainty regarding repayment if the company cannot secure additional funding or if it enters dissolution or bankruptcy proceedings.
• Employees may be impacted by potential cost reductions or operational changes if the company is forced to reduce spending.
• Suppliers may face extended payment terms if the company faces liquidity constraints.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement (closing bid price of $1.00 for 10 consecutive business days) by February 1, 2027.
• Regain compliance with Nasdaq's minimum stockholders' equity requirement (at least $2.5 million) by December 31, 2026.
• Launch new Zola Espresso product in November 2026.
• Launch new Zola 10.5-ounce slim-can line in the first half of 2027.
• Continue to monitor and address potential delisting from Nasdaq.
• Seek additional funding through debt or equity financings or asset sales.
• Actively evaluate and potentially pursue merger, acquisition, or other strategic transactions.

Key Dates

Recommendation

The company's severe financial distress, including substantial doubt about its going concern status, ongoing net losses, and critical Nasdaq listing compliance issues, presents a high level of risk. Despite some revenue growth, these fundamental challenges outweigh the positives, making it a sell recommendation for seasoned investors.

Keywords

Arcadia Biosciences, Zola Coconut Water, Form 10-Q, Quarterly Report, Financial Statements, Going Concern, Nasdaq Listing, Revenue Growth